Printer Friendly
The Free Library
14,787,283 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Antares Pharma to Present at BMO Capital Markets Focus on Healthcare 2006 Investor Conference.


EWING, N.J. -- Antares Pharma, Inc. (Amex:AIS) announced that Jack E. Stover stover

stalks of maize plants from which mature corn cobs have been harvested as grain, or grain sorghum plants from which heads have also been removed. The stover is usually fed by turning the cattle into the field and is subject to fungal infection, sometimes causing mycotoxicosis.
, President & Chief Executive Officer is scheduled to present at the BMO BMO Bank of Montreal (Canada)
BMO Before Market Open
BMO Biometrics Management Office
BMO Ballistic Missile Office
BMO British Mathematical Olympiad
BMO Balkan Mathematical Olympiad
BMO Business Management Office
 Focus on Healthcare Conference on Wednesday, December 6, 2006 at 2:30 pm (ET) at the Millennium Broadway Hotel in New York City New York City: see New York, city.
New York City

City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S.
. A live webcast of the audio portion of this presentation will be available via http://www.bmocm.com/conferences/healthcare2006/default.aspx.

Antares Pharma

Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable in·ject·a·ble
adj.
Capable of being injected. Used of a drug.

n.
A drug or medicine that can be injected.
 device engineering capabilities. Antares' current technology platforms include its ATD ATD Anthropomorphic Test Dummy
ATD Attention to Detail
ATD Advanced Technology Demonstration
AtD Achieving the Dream
ATD Atmospheric Technology Division (US National Center for Atmospheric Research)
ATD Assistant Technical Director
[TM] Advanced Transdermal Delivery system transdermal delivery system: see skin patch. , and its related TecTix[TM] system for topical and transmucosal delivery, its Easy Tec[TM] oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex[TM] disposable mini-needle injection device and Valeo[TM]/Vision[R] reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline, if approved, will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares Pharma has corporate headquarters in Princeton Crossroads Corporate Center in Ewing, NJ, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 27, 2006
Words:225
Previous Article:Fitch Affirms Green Tree Servicing's Resi & Special Servicer Ratings.
Next Article:Women's Diagnostic Announces Name Change to Solis Women's Health.
Topics:



Related Articles
Antares Pharma to Present at the Friedman Billings Ramsey 2006 Growth Conference.
Antares Pharma to Present at UBS Global Life Sciences Conference.
Taking leadership to the bank: Canada's CFO of the year.(cfo interview)(Karen Maidment, Bank of Montreal)(Interview)
Antares Pharma to Present at Rodman & Renshaw 8th Annual Healthcare Conference.
Antares Pharma to Present at CIBC World Markets Seventeenth Annual Healthcare Conference.
Medtronic to Participate in the BMO Capital Markets Health Care Conference.
Antares Pharma Announces Notice of Allowance for Newest ATD(TM) Gel Patent.
Antares Receives $1.75 Million Milestone Payment.
Antares Pharma Announces Issuance of New Broad Patent Covering Multiple ATD(TM) Gel Formulations including Anturol(R), Elestrin(TM) and LibiGel(R).
Antares Pharma to Present at Friedman, Billings, Ramsey & Co. 2007 Growth Conference.

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles